Rate My Professor Anthony Firulli

Firulli's research investigates the bHLH Hand/Twist-family proteins, demonstrating their broad dimerization characteristics and how phosphoregulation influences partner choice. His group has established that gene dosage of these factors defines a bHLH code that orchestrates cell specification, differentiation, and morphological patterning, contributing to human diseases such as congenital heart defects. Key findings include the discovery that Hand1 expression in the first pharyngeal arch is dispensable for craniofacial morphogenesis but dimer mutants disrupt FGF and SHH signaling, causing mid-face clefting. They identified Hand1 transcriptional enhancers recapitulating expression in the first pharyngeal arch, sympathetic nervous system, and left ventricle. HAND1 influences cardiac conduction system morphogenesis, with human SNPs in its enhancer linked to conduction defects, replicated in gene-edited mice. For HAND2, studies show it acts downstream of NOTCH signaling in the endocardium; its loss causes tricuspid atresia and impacts shear stress pathways. Single-cell analyses revealed novel HAND2-dependent endocardial enhancers. Firulli's lab continues to map regulatory enhancers and downstream targets of Hand1 and Hand2 to uncover gene regulatory networks in embryogenesis. Notable publications include "Heart and extra-embryonic mesodermal defects in mouse embryos lacking the bHLH transcription factor Hand1" (Nature Genetics, 1998) and "The bHLH transcription factor Tcf21 is required for lineage-specific EMT of cardiac fibroblast progenitors" (Development, 2012). His work has secured major NIH funding, including a P01 renewal in 2023 for ventricular wall morphogenesis.